688293 奥浦迈
已收盘 03-03 15:00:00
资讯
新帖
简况
3月3日奥浦迈跌6.17%，招商医药健康产业股票基金重仓该股
证券之星 · 16:36
3月3日奥浦迈跌6.17%，招商医药健康产业股票基金重仓该股
每周股票复盘：奥浦迈（688293）2025年净利增98.07%
证券之星 · 03-01 02:33
每周股票复盘：奥浦迈（688293）2025年净利增98.07%
奥浦迈发布2025年度业绩快报，盈利0.417亿元
证券之星 · 02-27
奥浦迈发布2025年度业绩快报，盈利0.417亿元
奥浦迈（688293）披露全资子公司完成工商变更登记并换发营业执照公告，2月24日股价下跌1.03%
证券之星 · 02-24
奥浦迈（688293）披露全资子公司完成工商变更登记并换发营业执照公告，2月24日股价下跌1.03%
【机构调研记录】招商基金调研奥浦迈、多利科技等3只个股（附名单）
证券之星 · 02-10
【机构调研记录】招商基金调研奥浦迈、多利科技等3只个股（附名单）
【私募调研记录】鹿秀投资调研奥浦迈
证券之星 · 02-10
【私募调研记录】鹿秀投资调研奥浦迈
【私募调研记录】岳瀚资产调研奥浦迈
证券之星 · 02-10
【私募调研记录】岳瀚资产调研奥浦迈
每周股票复盘：奥浦迈（688293）拟用3亿元超募资金补流
证券之星 · 02-08
每周股票复盘：奥浦迈（688293）拟用3亿元超募资金补流
奥浦迈（688293）披露调整董事会人数及增选董事等议案，2月5日股价上涨4.13%
证券之星 · 02-05
奥浦迈（688293）披露调整董事会人数及增选董事等议案，2月5日股价上涨4.13%
股市必读：奥浦迈（688293）预计2025年全年归属净利润盈利约4200万元
证券之星 · 02-02
股市必读：奥浦迈（688293）预计2025年全年归属净利润盈利约4200万元
每周股票复盘：奥浦迈（688293）预计2025年扣非净利2100万
证券之星 · 02-01
每周股票复盘：奥浦迈（688293）预计2025年扣非净利2100万
奥浦迈：预计2025年全年归属净利润盈利约4200万元
证券之星 · 01-30
奥浦迈：预计2025年全年归属净利润盈利约4200万元
每周股票复盘：奥浦迈（688293）完成收购澎立生物100%股权
证券之星 · 01-18
每周股票复盘：奥浦迈（688293）完成收购澎立生物100%股权
奥浦迈（688293）公司公告补选第二届董事会独立董事，1月16日股价下跌1.24%
证券之星 · 01-16
奥浦迈（688293）公司公告补选第二届董事会独立董事，1月16日股价下跌1.24%
奥浦迈（688293）披露发行股份及支付现金购买资产之标的资产过户完成公告，1月14日股价上涨1.49%
证券之星 · 01-14
奥浦迈（688293）披露发行股份及支付现金购买资产之标的资产过户完成公告，1月14日股价上涨1.49%
奥浦迈涨5.05%，开源证券一个月前给出“买入”评级
证券之星 · 01-13
奥浦迈涨5.05%，开源证券一个月前给出“买入”评级
CRO概念表现强势，奥浦迈大涨超7%
证券之星 · 01-13
CRO概念表现强势，奥浦迈大涨超7%
每周股票复盘：奥浦迈（688293）及子公司通过高新认定
证券之星 · 01-11
每周股票复盘：奥浦迈（688293）及子公司通过高新认定
奥浦迈（688293）披露独立董事变更公告，1月7日股价下跌0.33%
证券之星 · 01-07
奥浦迈（688293）披露独立董事变更公告，1月7日股价下跌0.33%
每周股票复盘：奥浦迈（688293）获证监会批复并购澎立生物
证券之星 · 01-02
每周股票复盘：奥浦迈（688293）获证监会批复并购澎立生物
加载更多
公司概况
公司名称：
上海奥浦迈生物科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-09-02
主营业务：
上海奥浦迈生物科技股份有限公司的主营业务是细胞培养产品与服务。公司的主要产品是高品质培养基、抗体药物开发CDMO服务平台。
发行价格：
80.20
{"stockData":{"symbol":"688293","market":"SH","secType":"STK","nameCN":"奥浦迈","latestPrice":45.6,"timestamp":1772521200000,"preClose":48.6,"halted":0,"volume":2849977,"delay":0,"changeRate":-0.0617,"floatShares":113999999,"shares":130000000,"eps":0.3326,"marketStatus":"已收盘","change":-3,"latestTime":"03-03 15:00:00","open":48.99,"high":49.24,"low":45.45,"amount":133000000,"amplitude":0.078,"askPrice":45.7,"askSize":24,"bidPrice":45.6,"bidSize":18,"shortable":0,"etf":0,"ttmEps":0.3326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772587800000},"marketStatusCode":5,"adr":0,"adjPreClose":48.6,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772501400000,1772508600000],[1772514000000,1772521200000]],"highLimit":53.46,"lowLimit":43.74,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":130036026,"isCdr":false,"pbRate":2.82,"roa":"--","peRate":137.101624,"roe":"2.34%","epsLYR":0.19,"committee":0.128205,"marketValue":5930000000,"turnoverRate":0.025,"status":1,"afterMarket":{"amount":0,"volume":0,"close":45.6,"buyVolume":802,"sellVolume":0,"time":1772523237558,"indexStatus":"已收盘 03-03 15:30:00","preClose":48.6},"floatMarketCap":5190000000},"requestUrl":"/m/hq/s/688293","defaultTab":"news","newsList":[{"id":"2616120093","title":"3月3日奥浦迈跌6.17%，招商医药健康产业股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616120093","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616120093?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:36","pubTimestamp":1772526994,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日奥浦迈跌6.17%创60日新低，收盘报45.6元，换手率2.5%，成交量2.85万手，成交额1.33亿元。重仓奥浦迈的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级1家，增持评级2家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共16家，其中持有数量最多的公募基金为招商基金的招商医药健康产业股票。该公募基金现任基金经理为李佳存。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300029019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2616684302","title":"每周股票复盘：奥浦迈（688293）2025年净利增98.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616684302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616684302?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:33","pubTimestamp":1772303590,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，奥浦迈报收于50.92元，较上周的52.64元下跌3.27%。本周，奥浦迈2月24日盘中最高价报53.06元。本周关注点业绩披露要点：奥浦迈2025年归属净利润同比增长98.07%。业绩披露要点奥浦迈发布2025年度业绩快报，营业总收入354,913,388.11元，同比增长19.40%；营业利润49,601,089.09元，同比增长35.56%；归属于母公司所有者的净利润41,698,525.76元，同比增长98.07%。扣除非经常性损益后的净利润同比增长216.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2614835321","title":"奥浦迈发布2025年度业绩快报，盈利0.417亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614835321","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614835321?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:17","pubTimestamp":1772183828,"startTime":"0","endTime":"0","summary":"报告期末，公司总资产为224,661.81万元，相较报告期初减少1.73%；归属于母公司的所有者权益210,047.12万元，相较报告期初增加0.18%。截至本报告期末，共有327个已确定中试工艺的药品研发管线使用公司的细胞培养基产品，整体相较2024年末增加80个，充分体现了市场对公司产品与技术实力的广泛认可。基于该项认定，公司适用的企业所得税税率自25%降至15%，对本报告期内所得税费用的减少产生积极影响，贡献约1,100.00万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700028495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2613679772","title":"奥浦迈（688293）披露全资子公司完成工商变更登记并换发营业执照公告，2月24日股价下跌1.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613679772","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613679772?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:51","pubTimestamp":1771930273,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，奥浦迈报收于52.1元，较前一交易日下跌1.03%，最新总市值为67.75亿元。该股当日开盘52.97元，最高53.06元，最低51.7元，成交额达3331.74万元，换手率为0.56%。奥浦迈近日发布《关于全资子公司完成工商变更登记并换发营业执照的公告》。公告显示，公司全资子公司澎立生物医药技术（上海）股份有限公司已完成公司类型变更等工商变更登记，并取得上海市市场监督管理局换发的《营业执照》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2610667426","title":"【机构调研记录】招商基金调研奥浦迈、多利科技等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2610667426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610667426?lang=zh_cn&edition=full","pubTime":"2026-02-10 08:12","pubTimestamp":1770682355,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及2月9日披露的机构调研信息，招商基金近期对3家上市公司进行了调研，相关名单如下：1）奥浦迈 调研纪要：从2024年开始，创新药行业投融资环境回暖，2025年中国创新药BD交易总金额达约1,388亿美元，首付款约75亿美元，均创历史新高。截至2025年10月31日，澎立生物在手订单金额2.52亿元，同比增长37.68%。奥浦迈2025年归母净利润约4200万元，扣非净利润约2100万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000005991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","001311","BK0264","688293"],"gpt_icon":0},{"id":"2610780667","title":"【私募调研记录】鹿秀投资调研奥浦迈","url":"https://stock-news.laohu8.com/highlight/detail?id=2610780667","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610780667?lang=zh_cn&edition=full","pubTime":"2026-02-10 08:12","pubTimestamp":1770682330,"startTime":"0","endTime":"0","summary":"根据市场公开信息及2月9日披露的机构调研信息，知名私募鹿秀投资近期对1家上市公司进行了调研，相关名单如下：1）奥浦迈 调研纪要：从2024年开始，创新药行业投融资环境回暖，2025年中国创新药BD交易总金额达约1,388亿美元，首付款约75亿美元，均创历史新高。奥浦迈收购澎立生物后，将于2026年开始全年并表，公司将形成“细胞培养基+CRDMO”一体化服务模式，实现客户资源双向导流。奥浦迈2025年归母净利润约4200万元，扣非净利润约2100万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026021000005950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2610966778","title":"【私募调研记录】岳瀚资产调研奥浦迈","url":"https://stock-news.laohu8.com/highlight/detail?id=2610966778","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610966778?lang=zh_cn&edition=full","pubTime":"2026-02-10 08:12","pubTimestamp":1770682329,"startTime":"0","endTime":"0","summary":"根据市场公开信息及2月9日披露的机构调研信息，知名私募岳瀚资产近期对1家上市公司进行了调研，相关名单如下：1）奥浦迈 调研纪要：从2024年开始，创新药行业投融资环境回暖，2025年中国创新药BD交易总金额达约1,388亿美元，首付款约75亿美元，均创历史新高。奥浦迈2025年归母净利润约4200万元，扣非净利润约2100万元。公司已获得中国证券投资基金业协会的私募基金管理人资格，并成为中基协观察会员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026021000005949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2609253815","title":"每周股票复盘：奥浦迈（688293）拟用3亿元超募资金补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2609253815","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609253815?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:45","pubTimestamp":1770486315,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，奥浦迈报收于55.9元，较上周的50.38元上涨10.96%。本周，奥浦迈2月6日盘中最高价报57.85元。2月3日盘中最低价报48.26元。奥浦迈当前最新总市值63.63亿元，在生物制品板块市值排名40/51，在两市A股市值排名2926/5186。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2609301161","title":"奥浦迈（688293）披露调整董事会人数及增选董事等议案，2月5日股价上涨4.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609301161","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609301161?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:43","pubTimestamp":1770302594,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，奥浦迈报收于52.42元，较前一交易日上涨4.13%，最新总市值为59.66亿元。该股当日开盘49.72元，最高52.55元，最低49.72元，成交额达8134.59万元，换手率为1.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2608888104","title":"股市必读：奥浦迈（688293）预计2025年全年归属净利润盈利约4200万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608888104","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608888104?lang=zh_cn&edition=full","pubTime":"2026-02-02 05:08","pubTimestamp":1769980096,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，奥浦迈报收于50.38元，下跌1.93%，换手率1.24%，成交量1.42万手，成交额7147.94万元。奥浦迈发布业绩预告，预计2025年全年扣非后净利润盈利约2100万元。公司公告汇总上海奥浦迈生物科技股份有限公司预计2025年年度实现归属于母公司所有者的净利润4,200.00万元左右，同比增长约99.50%；扣除非经常性损益后的净利润2,100.00万元左右，同比增长约218.86%。本次计提减少公司2025年度合并利润总额1,912.81万元，最终数据以会计师事务所审计结果为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293"],"gpt_icon":0},{"id":"2608705090","title":"每周股票复盘：奥浦迈（688293）预计2025年扣非净利2100万","url":"https://stock-news.laohu8.com/highlight/detail?id=2608705090","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608705090?lang=zh_cn&edition=full","pubTime":"2026-02-01 04:08","pubTimestamp":1769890091,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，奥浦迈报收于50.38元，较上周的57.0元下跌11.61%。本周，奥浦迈1月26日盘中最高价报57.31元。业绩披露要点奥浦迈发布业绩预告，预计2025年全年扣非后净利润盈利约2100万元，归属净利润盈利约4200万元。归属于母公司所有者的净利润同比增长约99.50%，扣除非经常性损益后的净利润同比增长约218.86%。本次计提减少公司2025年度合并利润总额1,912.81万元，最终数据以会计师事务所审计结果为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2607437090","title":"奥浦迈：预计2025年全年归属净利润盈利约4200万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607437090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607437090?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:44","pubTimestamp":1769762675,"startTime":"0","endTime":"0","summary":"证券之星消息，奥浦迈发布业绩预告，预计2025年全年归属净利润盈利约4200万元。同时,基于《企业会计准则》等相关要求,公司2025年度计提存货跌价损失约356.78万元。上述三项资产减值损失共计约1,912.81万元,对公司2025年度的净利润产生了较大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000028152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293"],"gpt_icon":0},{"id":"2604923006","title":"每周股票复盘：奥浦迈（688293）完成收购澎立生物100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923006?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:29","pubTimestamp":1768678148,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，奥浦迈报收于58.0元，较上周的52.45元上涨10.58%。本周关注点公司公告汇总：奥浦迈完成收购澎立生物100%股权，持股比例达100%。公司公告汇总奥浦迈完成通过发行股份及支付现金方式购买澎立生物医药技术（上海）股份有限公司100%股权的过户手续，公司直接持有澎立生物374,808,585股，持股比例100%。上海市方达律师事务所出具法律意见书，确认本次资产过户合法合规，澎立生物已成为奥浦迈全资子公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2603994108","title":"奥浦迈（688293）公司公告补选第二届董事会独立董事，1月16日股价下跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603994108","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603994108?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:38","pubTimestamp":1768574294,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，奥浦迈报收于58.0元，较前一交易日下跌1.24%，最新总市值为66.02亿元。该股当日开盘58.38元，最高59.12元，最低57.72元，成交额达8165.02万元，换手率为1.23%。近日，上海奥浦迈生物科技股份有限公司召开2026年第一次临时股东会，审议通过《关于补选公司第二届董事会独立董事的议案》。上海市方达律师事务所对本次会议进行了见证并出具法律意见书，认为会议召集、召开程序合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2603420612","title":"奥浦迈（688293）披露发行股份及支付现金购买资产之标的资产过户完成公告，1月14日股价上涨1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603420612","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603420612?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:41","pubTimestamp":1768401671,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，奥浦迈报收于56.59元，较前一交易日上涨1.49%，最新总市值为64.41亿元。近日，奥浦迈发布关于发行股份及支付现金购买资产并募集配套资金之标的资产过户完成的公告。公告显示，上海奥浦迈生物科技股份有限公司通过发行股份及支付现金方式购买澎立生物医药技术（上海）股份有限公司100%股权，标的资产已过户完成，公司直接持有澎立生物374,808,585股，持股比例100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400041609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2603054365","title":"奥浦迈涨5.05%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2603054365","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603054365?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:36","pubTimestamp":1768289805,"startTime":"0","endTime":"0","summary":"今日奥浦迈涨5.05%，收盘报55.76元。2025年11月17日，开源证券研究员余汝意,聂媛媛,石启正发布了对奥浦迈的研报《公司信息更新报告：培养基业务持续高增长，商业化管线项目数量新高》，该研报对奥浦迈给出“买入”评级。研报中预计公司2025-2027年归母净利润分别为0.75/1.02/1.33亿元，EPS为0.66/0.89/1.17元，当前股价对应P/E分别为89.6/65.7/50.1倍，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为开源证券的聂媛媛。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300020458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","161027"],"gpt_icon":0},{"id":"2603571529","title":"CRO概念表现强势，奥浦迈大涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603571529","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603571529?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:39","pubTimestamp":1768275598,"startTime":"0","endTime":"0","summary":"1月13日，A股CRO概念强势拉升，相关概念股普遍上涨，其中奥浦迈盘中一度大涨超7%。截至午间收盘，奥浦迈上涨6.12%，报56.33元/股，换手率1.52%，成交额9584.41万元。财报显示，奥浦迈2025年前三季度实现营业收入2.72亿元，同比增长25.79%。华西证券指出，奥浦迈作为国产培养基市场龙头，持续受益于国内生物药市场的蓬勃发展和国产替代，且考虑到战略布局的CDMO业务与培养基业务呈现协同发展，公司未来几年将继续保持高速增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026011300016544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2602076535","title":"每周股票复盘：奥浦迈（688293）及子公司通过高新认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2602076535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602076535?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:30","pubTimestamp":1768073428,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，奥浦迈报收于52.45元，较上周的49.0元上涨7.04%。本周，奥浦迈1月8日盘中最高价报52.83元。本周关注点公司公告汇总：奥浦迈及全资子公司通过高新技术企业认定，三年内享15%所得税优惠。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0},{"id":"2601801845","title":"奥浦迈（688293）披露独立董事变更公告，1月7日股价下跌0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801845","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601801845?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:26","pubTimestamp":1767795982,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，奥浦迈报收于51.51元，较前一交易日下跌0.33%，最新总市值为58.63亿元。该股当日开盘51.92元，最高52.5元，最低50.95元，成交额达9342万元，换手率为1.59%。近日，奥浦迈发布公司公告，披露独立董事变更事项。公告称，公司董事会收到独立董事陶化安先生的书面辞职报告，其因个人原因辞去独立董事及董事会专门委员会相关职务。为确保董事会正常运作，董事会提名文光伟先生为第二届董事会独立董事候选人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700038989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688293"],"gpt_icon":0},{"id":"2600375039","title":"每周股票复盘：奥浦迈（688293）获证监会批复并购澎立生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2600375039","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600375039?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:50","pubTimestamp":1767297019,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，奥浦迈报收于52.32元，较上周的52.66元下跌0.65%。本周关注点公司公告汇总：奥浦迈获证监会同意注册批复，将发行股份及支付现金购买澎立生物100%股权。奥浦迈收到中国证券监督管理委员会批复，同意公司发行股份及支付现金购买澎立生物医药技术（上海）股份有限公司100%股权，并向不超过35名特定投资者发行股票募集配套资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688293","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772548289136,"stockEarnings":[{"period":"1week","weight":-0.0767},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0342},{"period":"6month","weight":-0.0977},{"period":"1year","weight":0.1389},{"period":"ytd","weight":-0.0082}],"compareEarnings":[{"period":"1week","weight":0.0246},{"period":"1month","weight":0.0157},{"period":"3month","weight":0.0731},{"period":"6month","weight":0.0968},{"period":"1year","weight":0.2595},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海奥浦迈生物科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"3682人(较上一季度增加14.63%)","perCapita":"30912股","listingDate":"2022-09-02","address":"上海市浦东新区紫萍路908弄28号","registeredCapital":"13003万元","survey":" 上海奥浦迈生物科技股份有限公司的主营业务是细胞培养产品与服务。公司的主要产品是高品质培养基、抗体药物开发CDMO服务平台。","listedPrice":80.2},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥浦迈(688293)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥浦迈(688293)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥浦迈,688293,奥浦迈股票,奥浦迈股票老虎,奥浦迈股票老虎国际,奥浦迈行情,奥浦迈股票行情,奥浦迈股价,奥浦迈股市,奥浦迈股票价格,奥浦迈股票交易,奥浦迈股票购买,奥浦迈股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥浦迈(688293)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥浦迈(688293)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}